ATE358129T1 - 1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas - Google Patents

1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas

Info

Publication number
ATE358129T1
ATE358129T1 AT03747309T AT03747309T ATE358129T1 AT E358129 T1 ATE358129 T1 AT E358129T1 AT 03747309 T AT03747309 T AT 03747309T AT 03747309 T AT03747309 T AT 03747309T AT E358129 T1 ATE358129 T1 AT E358129T1
Authority
AT
Austria
Prior art keywords
antipsychotics
hexahydro
quinoline derivatives
obesity agents
obesity
Prior art date
Application number
AT03747309T
Other languages
English (en)
Inventor
P Sivaramakrishnan Ramamoorthy
Robert Emmett Mcdevitt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE358129T1 publication Critical patent/ATE358129T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
AT03747309T 2002-04-25 2003-04-24 1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas ATE358129T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37615302P 2002-04-25 2002-04-25

Publications (1)

Publication Number Publication Date
ATE358129T1 true ATE358129T1 (de) 2007-04-15

Family

ID=29270769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747309T ATE358129T1 (de) 2002-04-25 2003-04-24 1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas

Country Status (17)

Country Link
US (2) US7071185B2 (de)
EP (1) EP1497294B1 (de)
JP (1) JP2005529894A (de)
CN (2) CN100379735C (de)
AR (1) AR039670A1 (de)
AT (1) ATE358129T1 (de)
AU (1) AU2003243160B2 (de)
BR (1) BR0309463A (de)
CA (1) CA2482455A1 (de)
DE (1) DE60312838T2 (de)
DK (1) DK1497294T3 (de)
ES (1) ES2282652T3 (de)
MX (1) MXPA04010374A (de)
PT (1) PT1497294E (de)
SI (1) SI1497294T1 (de)
TW (1) TW200307682A (de)
WO (1) WO2003091251A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
TW200635926A (en) * 2004-11-05 2006-10-16 Wyeth Corp Metabolites of ceratin [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
AU2007230997A1 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
EP1998773A2 (de) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Neue therapeutische kombinationen zur behandlung von depression
US20070225278A1 (en) * 2006-03-24 2007-09-27 Wyeth Methods for treating cognitive and other disorders
EP2727585A1 (de) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo Screening-Methode
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
EP2789338A3 (de) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Kondensiertes Pyridinderivat und seine Verwendung
EP2510949A4 (de) 2009-12-11 2013-11-13 Astellas Pharma Inc Therapeutikum für fibromyalgie
CA2788416C (en) 2010-02-04 2018-08-14 The Board Of Trustees Of The University Of Illinois Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP6198715B2 (ja) * 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
AR092568A1 (es) 2012-09-14 2015-04-22 Abbvie Deutschland Derivados triciclicos de quinolinas y de quinoxalinas
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN107810175B (zh) 2015-01-29 2021-06-15 伊利诺伊大学评议会 作为选择性5-ht(2c)受体激动剂的环丙基甲胺
MA42527A (fr) * 2015-07-31 2021-04-07 Arena Pharm Inc Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
US10829877B2 (en) * 2018-08-27 2020-11-10 Nippon Mayer Ltd. Warp knitting machine, warp knitted fabric manufacturing method and warp knitted fabric

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US50300A (en) * 1865-10-03 John h
US422524A (en) * 1890-03-04 Marion c
US422657A (en) * 1890-03-04 Cane cutter or disintegrator
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
GB1120463A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of 1,3-diazafluoranthene-1-oxide
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
DE2443567C3 (de) * 1974-09-12 1980-04-10 Hoechst Ag, 6000 Frankfurt U3,4,7,8-Hexahydro-(6H)-pyrido- [U3-ef] -1,5benzodiazepin-2-one, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SU930902A1 (ru) 1980-12-18 1982-10-15 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные тиено [3,2=в] индола
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH0240379A (ja) 1988-07-28 1990-02-09 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体
JPH02180885A (ja) * 1988-09-01 1990-07-13 Glaxo Group Ltd ラクタム誘導体
EP0377238A1 (de) * 1988-12-22 1990-07-11 Duphar International Research B.V Annelierte Indolo(3,2-c)-lactame
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
JPH10237073A (ja) 1996-02-02 1998-09-08 Sumitomo Pharmaceut Co Ltd 新規な置換グアニジン誘導体およびその製法
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
CA2241891A1 (en) 1996-02-21 1997-08-21 Darwin Discovery Limited Quinolones and their therapeutic use
WO1997030999A1 (en) 1996-02-21 1997-08-28 Darwin Discovery Limited Quinolones and their therapeutic use
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
CA2324475A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
NZ512765A (en) 1998-12-17 2003-10-31 Wyeth Corp 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
ATE277048T1 (de) 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
JP2001089461A (ja) 1999-09-24 2001-04-03 Konica Corp テトラヒドロナフトジアゼピン類の製造方法及びスクアリリウム染料の製造方法
JP2003525252A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US6759405B2 (en) * 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6414144B1 (en) * 2000-11-03 2002-07-02 Wyeth Process for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi] indole derivatives
US6503900B2 (en) * 2000-11-03 2003-01-07 Wyeth [1,4]diazepino [6,7,1-jk ]carbazoles and derivatives
US6784172B2 (en) * 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AU2002227170A1 (en) 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031197A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
US6916922B2 (en) * 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
EP1330457B1 (de) 2000-11-03 2004-10-20 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
JP4386639B2 (ja) 2000-12-20 2009-12-16 ブリストル−マイヤーズ スクイブ カンパニー セロトニンアゴニストおよびアンタゴニストとしての置換されたピロロキノリン化合物およびピリドキノリン化合物
SK7042003A3 (en) * 2000-12-20 2004-07-07 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists
MXPA04001202A (es) 2001-08-06 2005-02-17 Pharmacia & Upjhon Company Ligandos tetraciclicos terapeuticamente utiles.
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents

Also Published As

Publication number Publication date
SI1497294T1 (sl) 2007-08-31
US20060154920A1 (en) 2006-07-13
AU2003243160A1 (en) 2003-11-10
DE60312838T2 (de) 2008-01-10
US7071185B2 (en) 2006-07-04
DE60312838D1 (de) 2007-05-10
CN100379735C (zh) 2008-04-09
MXPA04010374A (es) 2005-02-03
CN1662534A (zh) 2005-08-31
EP1497294B1 (de) 2007-03-28
CA2482455A1 (en) 2003-11-06
AR039670A1 (es) 2005-03-02
AU2003243160B2 (en) 2009-02-05
BR0309463A (pt) 2005-02-09
CN1955180A (zh) 2007-05-02
DK1497294T3 (da) 2007-07-16
WO2003091251A1 (en) 2003-11-06
ES2282652T3 (es) 2007-10-16
EP1497294A1 (de) 2005-01-19
US20040019040A1 (en) 2004-01-29
JP2005529894A (ja) 2005-10-06
PT1497294E (pt) 2007-06-12
TW200307682A (en) 2003-12-16

Similar Documents

Publication Publication Date Title
ATE358129T1 (de) 1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas
DE60304188D1 (de) Ä1,4ÜDIAZOCINOÄ7,8,1-hiÜINDOLDERIVATE ALS ANTIPSYCHOTISCHE MITTEL UND MITTEL GEGEN OBESITÄT
ATE398127T1 (de) (1,4)diazepino(6,7,1-ij)chinolinderivate als antipsychotische und mittel gegen fettleibigkeit
ATE413402T1 (de) Imidazoimidazole und -triazole als entzündungshemmende mittel
DE60127997D1 (de) 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika
ATE319686T1 (de) Mutilin-derivate und ihre anwendung als antibakterielle mittel
ATE354570T1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
DE60211532D1 (de) Pastöse zusammensetzung und diese enthaltende kosmetika
DE60317093D1 (de) Chinolin-; isochinolin- und chinazolinoxyalkylamide und ihre verwendung als fungizide
DE60301165D1 (de) Tragbares Endgerät, Zugriffskontrollverfahren und Zugriffskontrollprogramm
DE60329715D1 (de) Neue, sich als antiproliferative mittel eignende benzimidazolderivate
DE60214413D1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
DE60124040D1 (de) Raumabdeckung, Kofferraum und Antriebsvorrichtung
DE50214263D1 (de) Emollients und kosmetische zusammensetzungen enthaltend 2-methyl-1,3-propandioldiester
DE60209779D1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60218606D1 (de) Photodetektor und sein Betriebsverfahren
EP1578768A4 (de) Neuartige peptiddimere als agonisten des erythropoietinrezeptors und damit zusammenhängende syntheseverfahren und verwendungen
DE60303440D1 (de) Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
DE60008239D1 (de) Indolylpiperidinderivate als antihistaminische und antiallergische mittel
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
ATE538093T1 (de) Substituierte 2-carbonylamino-6- piperidinaminopyridine und substituierte 1- carbonylamino-3-piperidinaminobenzole als 5-ht1f- agonisten
FR2831442B1 (fr) Composition cosmetique mimant le sebum, et utilisations
DE60309233D1 (de) Vortex Spinnverfahren und Spinnmaschine
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
DE60201463D1 (de) Indanon-Derivate als Duftstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1497294

Country of ref document: EP

REN Ceased due to non-payment of the annual fee